References
- Speroff L, Glass R H., Kase N G. Steroid contraception. Clinical Gyncologic Endocrinology and Infertility. 4th ed., L Speroff, R H. Glass, N G. Kase. Williams & Wilkins, Baltimore 1989; 461–98
- Mall-Haefeli M, Werner-Zodrow I, Huber P R. Biochemical and clinical results with the new micropill Cilest. Aktuelle Aspekte der Hormonalen Kontrazeption, P J. Keller. Karger, Basel 1990; 1–12
- Wahl P, Walden C, Knopp R, et al. Effect of estrogen/ progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983; 308: 862–67
- Bradley D D., Wingerd J, Petitti D B., et al. Serum high-density lipoprotein cholesterol in women using oral contraceptives. estrogens and progestins. N Engl J Med 1978; 299: 17–20
- Phillips A. The selectivity of a new progestin. Acta Obstet Gynecol Scand Suppl 1990; 152: 21–24
- Phillips A, Hahn D W., Klimek S, McGuire J L. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception 1987; 36: 181–92
- McGuire J L., Phillips A, Hahn D W., et al. Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites. Am J Obstet Gynecol 1990; 163: 2127–31
- Phillips A, Hahn D W., McGuire J L. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity. Am J Obstet Gynecol 1991; 165: 1611
- Phillips A, Demarest K, Hahn D W., Wong F, McGuire J L. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 1990; 41(4)399–410
- Anderson D C. Sex-hormone-binding globulin. Clin Endocrinol 1974; 3: 69–96
- Victor A, Weiner E, Johansson E D B. Sex hormone binding globulin: the carrier protein for d-norgestrel. J Clin Endocrinol Metab 1976; 43: 244–47
- Phillips A, Hahn D W., McGuire J L. Relative binding affinity of norgestimate and other progestins for human sex hormone-binding globulin. Steroids 1990; 55: 373–5
- Chapdelaine A, Desmarais J L., Derman R J. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil 1989; 34: 347–52
- Corson S L. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials. Acta Obstet Gynecol Scand Suppl 1990; 152: 25–31
- Becker H. Supportive European data on a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand Suppl 1990; 152: 33–9
- Larsson-Cohn U, Fahraeus L, Wallentin L, Zador G. Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive. Fertil Steril 1981; 35: 172–9
- El Makhzangy M N., Wynn V, Lawrence D M. Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids. Clin Endocrinol 1979; 10: 39–45
- London R S., Chapdelaine A, Upmalis D, et al. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Sand Suppl 1992; 71(9)14
- Grunwald K, Rabe T, Runnebaum B. Clinical tolerance of a low-dose norgestimate-containing combination oral contraceptive (Cilest) in a West German multicenter study (Heidelberg Multicenter Oral Contraceptive Study). Aktuelle Aspekte der Hormonalen Kontraception, P J. Keller. Karger, Basel 1991; 67–78